Jenburkt Pharmaceuticals (524731) Q3 25/26 earnings summary

Executive summary

• Standalone unaudited financial results for the quarter and nine months ended 31st December 2025 were approved and reviewed by the Board and Audit Committee on 3rd February 2026.

Financial highlights

• Revenue from operations for Q3 FY26 was ₹4,302.39 lakhs, up from ₹3,689.30 lakhs in Q3 FY25.

• Total income for Q3 FY26 stood at ₹4,483.90 lakhs, compared to ₹3,847.48 lakhs in Q3 FY25.

• Profit before tax for Q3 FY26 was ₹829.68 lakhs, versus ₹951.33 lakhs in Q3 FY25.

• Profit after tax for Q3 FY26 was ₹593.14 lakhs, compared to ₹650.75 lakhs in Q3 FY25.

• Earnings per share for Q3 FY26 was ₹13.44, down from ₹14.75 in Q3 FY25.

Outlook and guidance

• Additional provision in employee benefit expense was made in compliance with the new Labour Codes on Wages 2019.